Unknown

Dataset Information

0

Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.


ABSTRACT: Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose. Immunization with opioid-based haptens conjugated to immunogenic carriers elicits opioid-specific antibodies that block opioid distribution to the brain and reduce opioid-induced behavior and toxicity in pre-clinical models. This study tested whether the efficacy of a lead oxycodone conjugate vaccine was improved by formulation in either aluminum hydroxide or the squalene-based oil-in-water emulsion MF59 adjuvant, which was recently FDA-approved for influenza vaccines in subjects 65+ years old. In adult BALB/c mice, alum formulation was more effective than MF59 at promoting the early expansion of hapten-specific B cells and the production of oxycodone-specific serum IgG antibodies, as well as blocking oxycodone distribution to the brain and oxycodone-induced motor activity. Alum was also more effective than MF59 at promoting early differentiation of peptide-specific MHCII-restricted CD4+ Tfh and GC-Tfh cells in adult C57Bl/6 mice immunized with a model peptide-protein conjugate. In contrast, alum and MF59 were equally effective in promoting hapten-specific B cells and peptide-specific MHCII-restricted CD4+ T cell differentiation in older C57Bl/6 mice. These data suggest that alum is a more effective adjuvant than MF59 for conjugate vaccines targeting synthetic small molecule haptens or peptide antigens in adult, but not aged, mice.

SUBMITTER: Robinson C 

PROVIDER: S-EPMC6605845 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.

Robinson Christine C   Baehr Carly C   Schmiel Shirdi E SE   Accetturo Claudia C   Mueller Daniel L DL   Pravetoni Marco M  

Human vaccines & immunotherapeutics 20190220 4


Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose. Immunization with opioid-based haptens conjugated to immunogenic carriers elicits opioid-specific antibodies that block opioid distribution to the brain and reduce opioid-induced behavior and toxicity in pre-clinical models. This study tested whether the efficacy of a lead oxycodone conjugate vaccine was i  ...[more]

Similar Datasets

| S-EPMC8624716 | biostudies-literature
| S-EPMC6724148 | biostudies-literature
| S-EPMC3541451 | biostudies-literature
| S-EPMC7069805 | biostudies-literature
2009-07-03 | E-TABM-506 | biostudies-arrayexpress
| S-EPMC7247356 | biostudies-literature
| S-EPMC5803373 | biostudies-literature
2016-05-29 | GSE72624 | GEO
| S-EPMC7319119 | biostudies-literature
| S-EPMC4462752 | biostudies-literature